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Abstract
Background—Antiretrovirals (ARV) that achieve adequate concentrations in anatomical sites of
transmission are of interest for HIV prevention. A Phase 1, open label, pharmacokinetic (PK)
study was performed to describe first dose and steady-state PK of the integrase inhibitor
dolutegravir (DTG) in blood plasma (BP), cervicovaginal fluid (CVF), cervical tissue (CT), and
vaginal tissue (VT) in HIV-1 negative women.
Methods—Eight healthy females given DTG 50mg daily for 5–7d had eleven paired BP and
CVF samples collected over 24h following the first dose (PK1) and multiple dosing (PK2). Each
woman underwent CT and VT biopsies at 1/4 time points at PK1 and PK2 to generate composite
PK profiles. DTG concentrations were analyzed by validated LC-MS/MS methods.
Noncompartmental PK analysis was performed and Spearman Rank Correlations determined
between matrices.
Results—BP AUCs were similar to previous reports and concentrations remained greater than
the protein-adjusted IC90 for wild-type HIV (64 ng/mL). CVF exposures were ~6% of BP with
low interindividual variability. CT and VT exposures were 7% of BP at PK1, and 9–10% of BP at
PK2 with 94% of samples >PA-IC90. CT and VT concentrations were correlated to each other
(rho=0.70, p=0.003), and to CVF at steady state (rho=0.52, p=0.04). Accumulation of DTG from
PK1 to PK2 occurred in BP, CT, and VT, but only marginally in CVF.
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Conclusions—DTG BP PK were consistent with previously published values. CVF, CT and VT
exposures were highly correlated. At PK2, DTG accumulated to a greater extent in tissue than in
BP or CVF, suggesting increased tissue affinity.
Keywords
dolutegravir; pharmacokinetics; cervicovaginal fluid; cervical tissue; vaginal tissue; female genital
tract
Introduction
GSK1349572 (dolutegravir, DTG) is an integrase strand transfer inhibitor (INSTI) currently
in clinical development. It has a 14-hour plasma half-life, which allows for once daily
dosing without the need for pharmacokinetic (PK) boosting. In SPRING-1, a Phase 2b dose-
ranging study in HIV-infected patients, 88–92% of patients dosed once daily with 10, 25,
and 50 mg of DTG had undetectable HIV RNA at 48 weeks, compared with 82% of those
taking the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) based on
the intention-to-treat (ITT) exposed population [1]. These subjects also received either
abacavir (ABC)/lamivudine (3TC) or tenofovir (TDF)/emtricitabine (FTC). Two Phase 3
studies have evaluated the use of DTG in treatment naïve patients. In SPRING-2, a double-
blind, active control, non-inferiority study, DTG 50mg daily was compared to the first
integrase inhibitor to market, raltegravir (RAL) 400mg twice daily, each given with either
ABC/3TC or TDF/FTC [2]. Using an FDA snapshot analysis of the ITT exposed population,
at 48 weeks, 88% of the patients receiving DTG and 85% of those receiving RAL had HIV
RNA suppressed to <50 copies/mL. In SINGLE, a double blind, double dummy, non-
inferiority study, DTG given with ABC/3TC was compared to EFV given as the fixed-dose
combination with TDF/FTC [3]. Also using an FDA snapshot analysis of the ITT exposed
population, at 48 weeks, 88% of DTG recipients and 81% of EFV recipients had HIV RNA
suppressed to <50 copies/mL primarily due to the higher discontinuation rates in the EFV
arm. Additionally, DTG has been shown to maintain efficacy in raltegravir experienced
patients when given twice daily in an open-label cohort study [4]. Based on the promising
results of these studies, DTG is a welcome addition to currently available antiretrovirals.
The purpose of this study is to describe first dose and steady state pharmacokinetics of DTG
in cervicovaginal fluid (CVF), vaginal tissue (VT) and cervical tissue (CT) compared to
blood plasma (BP) in HIV-1 negative women. Although current antiretroviral therapy
regimens decrease blood plasma HIV RNA to <50 copies/mL in a majority of patients, the
risk of HIV-1 transmission remains, as viral shedding in the female genital tract may be
incompletely suppressed [5,6]. To eradicate replication-competent virus at the site of
transmission, it is hypothesized that adequate local concentrations of antiretroviral drugs
must be achieved [7]. Understanding pharmacokinetic behavior of DTG in multiple female
biological compartments will inform its role in preventing viral replication in the genital
tract in HIV-infected women (particularly during acute HIV infection and in late-presenting
pregnancy), and its potential in protecting mucosal surfaces against HIV infection for
applications such as treatment as prevention, and post-exposure prophylaxis. This is the first
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study of female genital tract antiretroviral pharmacokinetics to be completed prior to market
approval.
Methods
Study Design and Population
The study was approved by the UNC Biomedical Institutional Review Board and performed
under FDA IND# 112,854. The trial was registered on clinicaltrials.gov under the identifier
NCT01404806. All study activities were carried out in accordance with the ethical standards
of the International Conference on Harmonisation E6 Good Clinical Practice guidances.
Informed consent was obtained on all participants prior to any study activities.
The women underwent screening within 45 days prior to enrollment. Screening procedures
consisted of a complete medical history and physical examination; 12-lead
electrocardiogram (ECG) with cardiology interpretation, comprehensive laboratory studies
(complete blood count with differential, liver function tests, serum chemistries, urinalysis,
and urine toxicology). Subjects were screened for active hepatitis B and hepatitis C, HIV,
and other sexually transmitted infections such as syphilis, gonorrhea, trichomonas and
chlamydia. Women underwent screening prior to study enrollment and DTG dosing.
Subjects were eligible to participate if they were females with regular menstrual cycles
between 18–35 years of age, inclusive at the date of screening, and had a Body Mass Index
(BMI) 18–30kg/m2 with total body weight greater than 50kg. Subjects were required to
have fully intact genital and gastrointestinal tracts, with documentation of a normal Pap
smear within one year. Subjects were excluded for any clinically significant abnormal lab
value, physical examination finding or clinical condition that would interfere with study
activities. Subjects were required to stop all prescription and nonprescription medications 7
days before and herbal supplements 14 days before study enrollment, and medications could
not be restarted until study completion. Subjects were limited to consumption of less than 14
alcoholic drinks per week [1 drink = 5 ounces (150mL) of wine or 12 ounces (360mL) of
beer or 1.5 ounces (45mL) of spirits], and acetaminophen at doses of <1gm/day.
All subjects had to use at least one acceptable form of contraception, including abstinence,
bilateral tubal ligation, condoms with spermicide or foam, stable male partner with
vasectomy or female only partners, or oral hormonal contraception started at least 3 months
prior to enrollment. Subjects agreed to remain abstinent from all sexual activity and
insertion of all vaginal products starting 72 hours prior to enrollment until completion of all
study activities. While taking DTG, the women were assessed for adverse events and
medication adherence daily in person or via telephone and using a standardized head-to-toe
assessment form. Vital signs, serum chemistries, CBC, and urine pregnancy test were
performed at each visit. All adverse events were graded by the study Physician Assistant and
study Physician using the Division of AIDS Table for Grading the Severity of Adult and
Pediatric Adverse Events.
Adams et al. Page 3






















Sample Collection and Processing
Subjects were admitted to the North Carolina Translational and Clinical Sciences (NC
TraCS) Institute Clinical and Translational Research Center (CTRC) on day 1 (first dose)
and either day 5, 6, or 7 of dosing with DTG 50mg daily. Steady-state conditions were
expected to be achieved within 5 days of dosing. Enrollment was scheduled 5–10 days after
the end of subject's menses. A witnessed DTG dose was given after an 8 hour fast and
standard research meals were provided throughout each 24 hour inpatient sampling period.
BP was collected in 3ml K2EDTA tubes (BD Diagnostics, Franklin Lakes, NJ) pre-dose,
then at 0.5, 1, 2, 3, 4, 6, 8, 12, 18 and 24 hours following each dose. At those same time
points, CVF was self-collected by the women using a volumetric aspiration device.
Additionally, BP and CVF samples were collected at 48 and 72 hours following the final
dose. Immediately following collection, the CVF was transferred from the vaginal aspirator
to a 2mL cryovial and frozen at −80°C. Within 1 hour after blood collection, K2EDTA tubes
stored on ice were processed by centrifugation at 800×g at 4°C for 10 minutes. The resultant
BP was then transferred to a 2ml cryovial and frozen at −80°C.
Vaginal and cervical tissues were collected by biopsy at one time point during each PK visit.
Two women were assigned to each of four time points (either 3, 6, 12, or 24 hours post-
dose). Briefly, subjects were placed in the dorsal lithotomy position. After speculum
insertion, the vaginal fornices and the entire cervix were anesthetized with topical 20%
benzocaine spray (HurriCaine™, Beutlich Pharmaceuticals, Waukegan, IL) and Lidocaine
Hydrochloride Oral Topical Solution 2% (Boehringer Ingelheim, Roxane Laboratories, Inc.,
Columbus, OH). Vaginal tissue biopsies were obtained at either the left or right vaginal
fornix. Cervical biopsies were obtained at either the 3 or 9 o'clock position. Biopsies at the
second time point were obtained at the opposite location. Approximately 4mm × 2mm ×
2mm specimen with a median (range) weight of 0.014 (0.007–0.066) grams, was obtained at
both the vaginal and cervical sites using Baby Tischler forceps (Cooper Surgical, Germany).
Samples were placed in separate labeled screw-capped polypropylene tubes, immediately
snap-frozen in liquid nitrogen, and stored at −80°C until analysis. In order to be considered
evaluable, subjects had to provide tissue and 80% of BP and CVF samples, including the
pre-dose sample and 24-hour sample at each PK visit.
Laboratory Analysis
Quantification of DTG plasma concentrations was performed by protein precipitation and
LC-MS/MS analysis. Calibration curves were obtained using a 1/concentration2 weighted
linear regression of analyte:internal standard peak area ratio versus nominal concentration.
Compilation of concentration results and descriptive statistical analyses were performed
using Sciex Analyst version 1.6.1. Thirty microliters of each stored plasma sample was
mixed with 600μL of acetonitrile containing the isotopically-labeled internal standard,
dolutegravir-d715N (DTG-IS). Following vortex and centrifugation, a portion of the
supernatant was diluted with 50:50 methanol:water prior to LC-MS/MS analysis. DTG was
eluted from a Varian (Agilent) Pursuit Diphenyl (2.1 × 50mm, 3μm particle size) analytical
column. An API- 5000 triple quadrupole mass spectrometer (AB Sciex, Foster City, CA)
was used to detect the analyte. For DTG, the precursor ion was 420m/z and the product ion
was 277m/z. For DTG-IS, the precursor ion was 428m/z and the product ion was 283m/z.
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Data were collected using AB Sciex Analyst Chromatography Software. The dynamic range
of the assay was 20–20,000 ng/mL. All calibrators and quality control (QC) samples were
within 15% of the nominal value for both within-day and between-day runs. The high,
medium, and low QC values used for plasma were 60.0, 600, and 16,000 ng/mL. Within-day
and between-day precision calculations were < 15%. The recovery range for DTG in plasma
was 98.0–103%, and the recovery of DTG-IS was 104%.
The extraction of DTG from CVF samples required a 5-fold dilution with 0.9% sodium
chloride solution prior to analysis to lower the viscosity of the CVF. This dilution allowed
for proper vortexing of the sample and facilitated quantitative transfer of the sample to the
extraction tube. Calibration standards and QC samples were prepared in 5-fold diluted
human CVF. The lower viscosity of the diluted CVF also allowed for accurate preparation
of standards and QCs. Since samples were diluted following collection, a 5-x dilution factor
was applied to all samples. Thirty microliters of each diluted CVF sample was mixed with
270 μL of acetonitrile containing DTG-IS. Following vortex and centrifugation, a portion of
the supernatant was diluted with 50:50 methanol:water. DTG was detected using identical
conditions to those described for plasma. The dynamic range of the assay was 1–1,000
ng/mL. The recovery range for DTG in CVF was 99.4–105%, and the recovery of DTG-IS
was 101%. All calibrators and quality controls samples were within 15% of the nominal
value. The low, medium, and high QC values used for CVF were 3.00, 30.0, and 800 ng/mL.
Within-day and between-day precision was < 15%.
In order to extract DTG from VT and CT samples, the tissue samples were initially
homogenized in 1mL of 80:20 water:acetonitrile. Fifty microliters of the resulting
homogenate was extracted by protein precipitation with acetonitrile containing DTG-IS.
Following vortex and centrifugation, a portion of the supernatant was diluted with water.
DTG was detected on an LC-MS/MS system using identical conditions as described above.
During method validation, calibration standards were prepared in human vaginal tissue
homogenate. QC samples were prepared in human vaginal and cervical tissue homogenates.
Method validation results indicated that calibration standards prepared in vaginal tissue
homogenate could be used successfully to quantitate DTG in both tissues. For sample
analysis, calibration standards and QC samples were prepared in human vaginal tissue
homogenate. The dynamic range of the assay was 0.2–200 ng/mL homogenate. The
recovery range of DTG in vaginal homogenate was 50.7–63.4%, and the recovery of DTG-
IS was 72.0%. The recovery range of DTG in cervical homogenate was 48.3–65.9% and the
recovery of DTG-IS was 71.4%. All calibrators and quality controls samples were within
15% of the nominal value with precision values < 15%. The low, medium, and high QC
values used for tissues were 0.600, 6.00, and 160 ng/mL.
Pharmacokinetic and Statistical Analysis
No formal sample size calculation was performed for this study. The sample size was chosen
to generate PK data adequate for understanding penetration of DTG into the female genital
tract considering the number sufficient to describe interpatient variability and prior similarly
performed PK studies. Noncompartmental analysis was performed using Phoenix Win
Nonlin v6.3 (Certara L.P.; St. Louis, MO). Cmax and Tmax were determined by
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visualization of the concentration-time curves and the area-under-the-concentration-time
curve over 24 hours (AUC0–24hr) was determined using the trapezoidal rule (linear up/log
down interpolation). BP and CVF half-life (t1/2) was determined by concentrations
collected 24–72h after the final dose. Composite AUCs were determined following the first
dose (PK1) and at steady state (PK2) for CT and VT using the geometric mean of the two
concentrations from each woman at each of the four biopsy time points. Summary statistics
and Spearman Rank Correlations between BP and CVF, CVF and GT, and CT and VT, were
calculated using SAS 9.3 (SAS Institute Inc; Cary, NC). PK parameters are separated by day
and by matrix and PK graphs were made using SigmaPlot 12.0 (Systat Software, Inc;
Chicago, IL). To calculate tissue penetration ratios, tissue VT and CT density was assumed
to be 1.05 g/mL. Concentrations below the limit of detection (BLD) were imputed as 0 and
concentrations below the limit of quantification (BLQ) were imputed as half the lower limit
of quantification (LLOQ) for the particular matrix (the lowest point on the standard curve).
Accumulation ratios were calculated between PK1 to PK2. Data are presented as median
(25th–75th percentile) unless otherwise noted.
Results
Demographics
Eleven women were enrolled to reach the target total of eight women completing
pharmacokinetic analysis for both PK1 and PK2. Three women dropped out during PK1 due
to an inability to collect at least 80% of the required CVF samples. These three women are
included in the adverse event data only. The median age of the eight evaluable women was
21 (range 18–27) years. The median BMI was 22.5 (range 21.0–29.2) kg/m2. All were
Caucasian. The median PK profiles for BP and CVF, as well as the composite PK profiles
for CT and VT are shown for PK1 (Figure 1) and for PK2 (Figure 2). The pharmacokinetic
parameters for all matrices at both PK1 and PK2 are summarized (Table 1).
Plasma Concentrations
Cmax and Tmax ranged from 1,350–4,380 ng/mL at 1–6 h after the first dose and 2,530–
5,590 ng/mL at 1–4 h after multiple dosing. The median (IQR) AUC0-24h for PK1 was
38,300 (31,600–45,400) ng*h/mL and for PK2 was 55,400 (43,300–62,200) ng*h/mL. The
half-life (t½) calculated using concentrations from 24–72h post-dose, was 14.8 (13.6–16.1)
h. The median (IQR) accumulation ratio of DTG in blood plasma over 7 days of dosing was
1.42 (1.28–1.50).
Cervicovaginal Fluid Concentrations
After a single dose, DTG was detected in cervicovaginal fluid (CVF) at 1 hour post dose in
3/8 women, and at 3 hour post dose in 8/8 women. The median (IQR) AUC0-24h for PK1
was 2,600 (1,280–8,100) ng*h/mL and for PK2 was 3,160 (2,820–5,220) ng*h/mL. Over
24h following the first dose, an elimination phase was not evident in 4/8 women, and a
reliable t1/2 could not be calculated. After 5–7 days of dosing, the median (IQR) t1/2 was
13.5 (11.1–14.9) h. The median (IQR) accumulation ratio of DTG in cervicovaginal fluid
was 0.82 (0.71–1.12) indicating no significant accumulation in the CVF with multiple
dosing. After a single dose, the AUC0-24h penetration ratios of CVF:BP were 0.07 (0.05–
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0.18); after multiple dosing, the ratios were 0.06 (0.04–0.11). These data demonstrates that
CVF exposure is approximately 6–7% of blood plasma exposure.
Genital Tract Tissue Concentrations
DTG concentrations were similar between CT and VT, after both single and multiple dosing
(Spearmans rho=0.70; p=0.003) (Figure 3). For CT, the composite AUC0-24h for PK1 and
PK2 was 2,750 ng*h/mL and 5,300 ng*h/mL, respectively. The accumulation ratio was
1.93. For vaginal tissue, the composite AUC0-24h for PK1 and PK2 was 2,730 ng*h/mL
and 4,740 ng*h/mL, respectively. The accumulation ratio was 1.74. These data suggest
greater drug accumulation of DTG in female genital tract tissues than in blood plasma.
Penetration ratios for VT and CT, in relation to blood plasma, were both 0.07 after a single
dose, and were 0.09–0.10 after multiple dosing. After a single dose of DTG, VT and CT
exposure was nearly double CVF concentrations at the same time points (CT:CVF ratio =
1.97; VT:CVF ratio = 1.95). After multiple dosing, tissue concentrations were 2–3 times
higher than CVF (CT:CVF ratio = 2.61; VT:CVF ratio = 2.34). The correlation between
CVF and GT was 0.15 (p=0.55) at PK1, but correlation between CVF and GT was 0.52
(p=0.04) at PK2 (Figure 4).
Adverse Events
Adverse event data include all eleven enrolled women who received at least one dose of
DTG. There were no serious adverse events and no women discontinued DTG as the result
of an adverse effect. Non-serious adverse events that were grade 1 or 2 and determined to be
possibly related to study drug involved 9 events in 8 women, and included headache (2
subjects), drowsiness (1 subject), dizziness/nausea (2 subjects), GI upset with gas (1
subject), lightheadedness upon standing (1 subject), and a grade 2 AST elevation at follow-
up (1 subject). One subject experienced scalp tingling and it was unknown whether this was
related to DTG. Adverse events that were determined to be unrelated to DTG administration
included one episode of fainting in one subject with IV insertion prior to the first dose of
DTG, irritation at the IV site (1 subject), and early menses (1 subject).
Discussion
The recently published trial, HPTN052, provided proof that effective antiretroviral treatment
of HIV infected individuals decreases the risk of HIV transmission to negative partners by
96% [8]. Evidence from 3 large clinical trials also demonstrates that tenofovir and
emtricitabine taken orally by HIV negative individuals can protect against infection through
heterosexual or homosexual transmission [9,10,11]. Evidence also exists, however, that not
all antiretrovirals penetrate the female genital tract equally well [12] and that viral shedding
in the female genital tract can persist in patients who are have undetectable HIV RNA in
blood plasma while on antiretroviral therapy [6,7]. Of importance to both treatment as
prevention and PrEP strategies, are antiretroviral agents with long half-lives that allow for
once daily dosing, with favorable adverse effect profiles and with the ability to penetrate the
mucosal compartments involved in HIV transmission (eg the female genital tract).
Adams et al. Page 7






















In this study, BP exposures of DTG after single and multiple dosing were found to be
consistent with previously published data [13]. Concentrations above the established protein
binding-adjusted IC90 of 64 ng/mL were achieved within 1 h of the first dose and remained
well above 64 ng/mL for the entire dosing interval within all subjects [14]. In 7/8 subjects,
BP concentrations remained above the IC90 at 72h after the final dose. These data
demonstrate prolonged exposure post-dose, and some degree of adherence “forgiveness”.
No serious adverse events were seen in this study. The adverse effects that were reported
were mild, and did not lead to discontinuation of DTG.
CVF concentrations were detectable 3 hrs after dosing in all subjects, and remained
detectable through 72h after the last dose. Overall DTG exposure was approximately 6% of
BP, with a CV% of 72% at steady state. In BP, DTG is >99% protein bound. Lopinavir,
atazanavir, amprenavir, ritonavir and efavirenz, which are also highly protein bound
(>85%), also have low penetration into CVF compared to blood plasma [12,15]. Raltegravir,
which has 83% protein binding and exhibits more variable blood plasma pharmacokinetics
(CV%=212) [16], has CVF exposures that are 100–400% of BP [17,18,19]. Elvitegravir, the
other INSTI currently on the market, has yet to establish female genital tract exposure.
However, it is also highly protein bound in BP (98%), and requires a pharmacokinetic
booster in order to achieve a half-life adequate for once daily dosing [20].
Protein binding in the CVF was not specifically measured in this study. If we assume
equivalent protein binding in CVF as in BP for DTG (>99%), concentrations above the
established protein binding-adjusted IC90 of 64 ng/mL were achieved within 6 h of the first
dose for 50% of the subjects and remained above 64 ng/mL for the entire dosing interval in
those same subjects. However, the major drug binding proteins alpha 1-acid glycoprotein
(AAG) and albumin, have concentrations in CVF that are <1% of what is measured in BP
[21]. Additionally, we have measured maraviroc CVF protein binding, and have found it to
be 10% of what is seen in blood plasma (7.6% versus ~76%) [22,23]. Since the protein-
unbound DTG IC50 is 0.21 ng/mL, if at least 90% of DTG in CVF is unbound, it is likely
that CVF exposures are above this value in all women by 4 h after a single dose, and
maintained in all women after multiple dosing out to at least 72h post-dose.
DTG concentrations in CVF correlated with CT and VT at steady state, suggesting CVF
may be a useful surrogate for tissue exposures. However, tissue sampling occurred at only a
small number of time points (1 per subject), and should be investigated further to establish
the relationship. DTG concentrations were similar in VT and CT, suggesting equal
distribution of drug throughout the lower female genital tract. Penetration ratios for VT and
CT, in relation to blood plasma, were 0.07 after a single dose and 0.09–0.10 after multiple
dosing. Female genital tract tissue:plasma AUC ratios for other antiretrovirals range from
0.6 (tenofovir) to 42 (emtricitabine) [7]. DTG concentrations in these tissues were > IC90 in
all eight women at all four steady state time points.
Additionally, a Phase II dose ranging study of dolutegravir identified an Emax model that
best explained the relationship between DTG trough concentrations and efficacy. The Emax
IC50 was 36 ng/ml. Trough concentrations were above this value in plasma in all subjects at
24 and 72 hours post dose. In CVF, trough concentrations above 36 ng/mL were achieved in
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7/8 subjects at 24 hours, but in no subjects by 48 hours. All CT and VT concentrations were
greater than 36 ng/mL after multiple dosing [13].
While it is important to investigate the pharmacokinetics in the female genital tract of
healthy women, it would also be of interest to determine the pharmacokinetics and viral load
suppression achieved in HIV infected women to determine the potential role ofdolutegravir
in treatment as prevention. Given the similar plasma concentrations of dolutegravir in both
healthy subjects and the HIV infected population, a significant difference in genital tract
penetration of dolutegravir would not be expected [13,14].
Conclusions
DTG plasma PK parameters after single and repeat doses were similar to previously reported
data. DTG exposure in CVF was 6% of plasma exposure under steady-state conditions.
Delayed Tmax was observed in CVF (Tmax=6hr) compared to plasma (Tmax=2hr). There
was only marginal accumulation after repeat dosing. DTG exposure in CT and VT were
similar and ~ 10% of plasma exposure under steady-state conditions. Higher accumulation
of DTG after multiple dosing was noted in both CT and VT compared to BP. DTG
concentrations were above the protein binding-adjusted IC90 in 100% of CT and 88% of VT
samples. DTG was well tolerated with no significant safety issues observed.
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Figure 1. Median (IQR) Concentrations of dolutegravir (DTG) in blood plasma (BP),
cervicovaginal fluid (CVF), cervical tissue (CT), and vaginal tissue (VT) following a single dose
of DTG
Following the first dose of DTG, the median (IQR) DTG concentrations at each time point
are plotted for BP and CVF and the median (range) DTG concentrations of the two
individual subject CT and VT samples at each time point are plotted as a composite
pharmacokinetic curve. Error bars represent IQR for BP and CVF, and the 2 individual
samples at each time point for CT and VT. The AUC ratio of CVF to BP is 0.07 (0.05–0.18)
following the first dose and the AUC ratio of tissue to CVF is 0.09.
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Figure 2. Pharmacokinetics of dolutegravir (DTG) in blood plasma (BP), cervicovaginal fluid
(CVF), cervical tissue (CT), and vaginal tissue (VT) at steady state
At steady state, the median (IQR) DTG concentrations at each time point are plotted for BP
and CVF and the median (range) DTG concentrations of the two individual subject CT and
VT samples at each time point are plotted as a composite pharmacokinetic curve. Error bars
represent IQR for BP and CVF, and the 2 individual samples at each time point for CT and
VT. The AUC ratio of CVF to BP is 0.06 (0.04–0.11) at steady state and the tissue
concentrations are 46–63% higher than in CVF.
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Figure 3. The correlation between cervical tissue (CT) and vaginal tissue (VT) dolutegravir
(DTG) concentrations
Individual concentration/time points are plotted for DTG in CT and VT. A significant
(p=0.003) correlation is noted between CT and VT concentrations (rho=0.70). A line of
unity is presented as reference.
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Figure 4. The correlation between cervicovaginal fluid (CVF) and genital tissue dolutegravir
(DTG) concentrations
Individual concentration/time points are plotted for DTG in genital tract tissues and in CVF.
a) Presents cervical tissue (circles) and vaginal tissues (squares) correlated with CVF
following the first dose of DTG. b) Presents vaginal tissue (circles) and vaginal tissues
(squares) correlated with CVF after multiple dosing. The correlation between CVF and
genital tissues (GT) at PK1 is 0.16 (p=0.55), and between CVF and GT at PK2 is 0.52
(p=0.04). A line of unity is presented as reference.
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